Company news
Compass Therapeutics, Inc. (NASDAQ:CMPX) news
Every Compass Therapeutics, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update
August 6, 2026
Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026
July 17, 2026
Compass Therapeutics to Participate in Upcoming June Investor Events
May 28, 2026
Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-C...
May 21, 2026
Compass Therapeutics Reports 2026 First Quarter Financial Results and Provides Corporate Update
May 5, 2026
Compass Therapeutics to Announce Topline Secondary Endpoints from the Phase 2/3 COMPANION-002 Study of Tovecimig in Patients with Biliary...
April 24, 2026
Compass Therapeutics Reports 2025 Financial Results and Provides Corporate Update
March 5, 2026
Compass Therapeutics Provides Corporate Update
January 6, 2026
Compass Therapeutics Announces Key Leadership Appointments
January 5, 2026
Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 5, 2026
Compass Therapeutics to Participate in the J.P. Morgan 2026 Healthcare Conference
December 17, 2025
Compass Therapeutics to Participate in Upcoming December Investor Events
November 25, 2025
Compass Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 5, 2025
Compass Therapeutics Presents Preclinical Data on CTX-10726, a Differentiated PD-1 x VEGF-A Bispecific Antibody, at the 40th Society for ...
November 4, 2025
Compass Therapeutics to Participate in Upcoming November Investor Events
November 3, 2025
Compass Therapeutics to Participate in Upcoming September Investor Events
August 26, 2025
Compass Therapeutics Announces Proposed Public Offering
August 12, 2025
Compass Therapeutics Announces Pricing of Upsized $120 Million Public Offering
August 12, 2025
Compass Therapeutics Reports 2025 Second Quarter Financial Results and Provides Corporate Update
August 11, 2025
Compass Therapeutics to Present Second Quarter Financial Results and Provide Business Update on August 11, 2025
August 8, 2025
Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference
May 28, 2025
Compass Therapeutics Reports 2025 First Quarter Financial Results and Provides Corporate Update
May 8, 2025
Compass Therapeutics to Participate in Upcoming May Investor Events
May 6, 2025
Compass Therapeutics Presents Data on Enhanced Efficacy of CTX-471 in Combination with Tovecimig in Checkpoint-Refractory Models at the A...
April 28, 2025
Compass Therapeutics Announces First Patient Dosed in an Investigator Sponsored Trial of Tovecimig in the First-Line Setting for Patients...
April 21, 2025
Compass Therapeutics to Participate in the Stifel 2025 Virtual Targeted Oncology Forum
April 2, 2025
Tovecimig (CTX-009) Meets Primary Endpoint in the Ongoing Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer
April 1, 2025
Compass Therapeutics to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized Phase 2/3 Study Evaluating Tovecimig...
March 31, 2025
Compass Therapeutics Reports 2024 Financial Results and Provides Corporate Update
February 27, 2025
Compass Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference
January 29, 2025
Compass Therapeutics Provides Corporate Update and Announces Advancement of a New Drug Candidate
January 8, 2025
Compass Therapeutics Appoints Biopharmaceutical Industry Leader Barry Shin as Chief Financial Officer
December 10, 2024
Compass Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference
December 2, 2024
Compass Therapeutics to Participate in Upcoming Investor Events
November 13, 2024
Compass Therapeutics Reports 2024 Third Quarter Financial Results and Provides Corporate Update
November 12, 2024
Compass Therapeutics Presents Novel Biomarker Data Related to CTX-471 Clinical Activity at the 39th Society for Immunotherapy of Cancer (...
November 8, 2024
Compass Therapeutics Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting
October 4, 2024
Compass Therapeutics Reports 2024 Second Quarter Financial Results and Provides Corporate Update
August 12, 2024
Compass Therapeutics to Participate in the Wedbush PacGrow Healthcare Conference
August 7, 2024
Compass Therapeutics Completes Patient Enrollment in COMPANION-002, a Randomized Study of CTX-009 in Combination with Paclitaxel, and Pro...
August 6, 2024
Compass Therapeutics Announces CEO Transition
May 28, 2024
Compass Therapeutics to Present Phase 1 Data for CTX-471, A Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients W...
May 23, 2024
Compass Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
May 14, 2024
Compass Therapeutics Reports 2024 First Quarter Financial Results and Provides Corporate Update
May 13, 2024
Compass Therapeutics Receives FDA Fast Track Designation for the Investigation of CTX-009 in Combination with Paclitaxel for the Treatmen...
April 25, 2024
Compass Therapeutics Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid Tumors
April 16, 2024
Compass Therapeutics Announces Poster Presentations at the Cholangiocarcinoma Foundation 2024 Annual Conference
April 12, 2024
Compass Therapeutics to Participate in the Stifel Targeted Oncology Days
April 10, 2024
Compass Therapeutics Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models at the 2024 American Associ...
April 9, 2024
Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update
March 21, 2024